Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;181(18):3303-3326.
doi: 10.1111/bph.16408. Epub 2024 May 15.

Montelukast improves disease outcome in SOD1G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity

Stefano Raffaele  1 , Nhung Nguyen  2 , Marco Milanese  2   3 , Francesca C Mannella  1 , Marta Boccazzi  1 , Giulia Frumento  2 , Giambattista Bonanno  2 , Maria P Abbracchio  4 , Tiziana Bonifacino  2   5 , Marta Fumagalli  1
Affiliations
Free article

Montelukast improves disease outcome in SOD1G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity

Stefano Raffaele et al. Br J Pharmacol. 2024 Sep.
Free article

Abstract

Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron (MN) loss and consequent muscle atrophy, for which no effective therapies are available. Recent findings reveal that disease progression is fuelled by early aberrant neuroinflammation and the loss of oligodendrocytes with neuroprotective and remyelinating properties. On this basis, pharmacological interventions capable of restoring a pro-regenerative local milieu and re-establish proper oligodendrocyte functions may be beneficial.

Experimental approach: Here, we evaluated the in vivo therapeutic effects of montelukast (MTK), an antagonist of the oligodendroglial G protein-coupled receptor 17 (GPR17) and of cysteinyl-leukotriene receptor 1 (CysLT1R) receptors on microglia and astrocytes, in the SOD1G93A ALS mouse model. We chronically treated SOD1G93A mice with MTK, starting from the early symptomatic disease stage. Disease progression was assessed by behavioural and immunohistochemical approaches.

Key results: Oral MTK treatment significantly extended survival probability, delayed body weight loss and ameliorated motor functionalityonly in female SOD1G93A mice. Noteworthy, MTK significantly restored oligodendrocyte maturation and induced significant changes in the reactive phenotype and morphological features of microglia/macrophages and astrocytes in the spinal cord of female SOD1G93A mice, suggesting enhanced pro-regenerative functions. Importantly, concomitant MN preservation has been detected after MTK administration. No beneficial effects were observed in male mice, highlighting a sex-based difference in the protective activity of MTK.

Conclusions and implications: Our results provide the first preclinical evidence indicating that repurposing of MTK, a safe and marketed anti-asthmatic drug, may be a promising sex-specific strategy for personalized ALS treatment.

Keywords: GPR17 receptor; SOD1G93A; amyotrophic lateral sclerosis; montelukast; neuroinflammation; oligodendrocytes.

PubMed Disclaimer

References

REFERENCES

    1. Amado, D. A., & Davidson, B. L. (2021). Gene therapy for ALS: A review. Molecular Therapy, 29, 3345–3358. https://doi.org/10.1016/j.ymthe.2021.04.008
    1. Angelini, J., Marangon, D., Raffaele, S., Lecca, D., & Abbracchio, M. P. (2021). The distribution of GPR17‐expressing cells correlates with white matter inflammation status in brain tissues of multiple sclerosis patients. International Journal of Molecular Sciences, 22, 4574. https://doi.org/10.3390/ijms22094574
    1. Bartlett, R., Sluyter, V., Watson, D., Sluyter, R., & Yerbury, J. J. (2017). P2X7 antagonism using brilliant blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice. PeerJ, 2017, e3064.
    1. Bonfanti, E., Bonifacino, T., Raffaele, S., Milanese, M., Morgante, E., Bonanno, G., Abbracchio, M. P., & Fumagalli, M. (2020). Abnormal upregulation of GPR17 receptor contributes to oligodendrocyte dysfunction in SOD1 G93A mice. International Journal of Molecular Sciences, 21, 2395. https://doi.org/10.3390/ijms21072395
    1. Bonfanti, E., Gelosa, P., Fumagalli, M., Dimou, L., Viganò, F., Tremoli, E., Cimino, M., Sironi, L., & Abbracchio, M. P. (2017). The role of oligodendrocyte precursor cells expressing the GPR17 receptor in brain remodeling after stroke. Cell Death & Disease, 8, e2871. https://doi.org/10.1038/cddis.2017.256

MeSH terms